Evaluation of a Novel Method for Hematocrit Level Determination
Recruitment status was Recruiting
The hematocrit level is defined as the ratio of plasma volume and red blood cell mass. Determination of this level is important for the diagnosis and follow-up of various hematological and renal disorders. In clinical practice, automated hematology analyzers are commonly used.
Recently, a new method for hematocrit level determination has been introduced which employs layered resonant piezoelectric sensors. In the present study this technique will be applied in blood samples of healthy subjects and compared to a standard laboratory method.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Evaluation of a Novel Method for Hematocrit Level Determination|
- Correlation of hematocrit level determined by two different techniques [ Time Frame: 5 minutes ] [ Designated as safety issue: No ]
|Study Start Date:||December 2009|
|Estimated Study Completion Date:||February 2011|
|Estimated Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Hematocrit level of each subject will be assessed by two different techniques
Other: Blood draw
A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
|Contact: Gerhard Garhofer, MD||0043-1-40400 ext firstname.lastname@example.org|
|Department of Clinical Pharmacology, Medical University of Vienna||Recruiting|
|Vienna, Austria, 1090|
|Contact: Gerhard Garhofer, MD 0043-1-40400 ext 2981 email@example.com|
|Principal Investigator: Gerhard Garhofer, MD|
|Principal Investigator:||Gerhard Garhofer, MD||Department of Clinical Pharmacology, Medical University of Vienna|